Plasma Cell Leukemia Clinical Trials in Tianjin, Tianjin Municipality
3 recruitingTianjin, Tianjin Municipality, China
Showing 1–3 of 3 trials
Recruiting
Phase 1Phase 2
Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM
Plasma Cell LeukemiaUltra High Risk mm (uhr-mm), 18-70 Years Old, Suitable for ASCT. And Meet Any of the Following uhr-mm DefinitionsCytogenetics Ultra High Risk+4 more
Institute of Hematology & Blood Diseases Hospital, China50 enrolled1 locationNCT07109323
Recruiting
Phase 2
ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia
Multiple Myeloma, Plasma Cell Leukemia
Institute of Hematology & Blood Diseases Hospital, China20 enrolled1 locationNCT07106684
Recruiting
Early Phase 1
A Study of CT0596 in Plasma Cell Leukemia
Plasma Cell Leukemia
Institute of Hematology & Blood Diseases Hospital, China27 enrolled1 locationNCT06988059